Showing results 3 to 7 of 7
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013 | - | ||
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Hepatology | 2011 | ||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | ||
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Journal:Journal for ImmunoTherapy of Cancer | 2021 | ||
Treatment before liver transplantation for HCC Journal:Annals of Surgical Oncology | 2008 |